New Delhi: Diversified entity ITC on Thursday notified that the company is developing a nasal spray for the prevention of COVID-19. The company has also initiated clinical trials for the same.
The nasal spray is developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru. The company has also revealed its plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals, PTI reported citing its sources.
A spokesperson of ITC said, “We are unable to share more details at the current moment as the clinical trials are underway.”
The spokesperson declined to comment on a detailed query that seeks information on where is the clinical trial being done, from where the commercial production would be done, when approved and under what brand the nasal spray would be marketed.
However, sources said the company had received approvals from ethics committees and is registered with Clinical Trial Registry-India (CTRI) for clinical trials of the nasal spray which is designed to arrest the virus at the entry point in the nasal cavity itself.
The officials further said that the product has the potential to be effective and safe in preventing infection and transmission of COVID-19 along with the existing measures of hygiene recommended by health authorities.
ITC’s LSTC has been at the core of the company’s drive for science-led product innovation to support and build its wide range of product portfolio.
The company’s research and development teams were instrumental in developing a range of innovative health and hygiene offerings that were commercially made available under the Savlon brand, during the pandemic.